144 related articles for article (PubMed ID: 20127278)
1. The association between ERCC2 Asp312Asn polymorphism and breast cancer risk: a meta-analysis involving 22,766 subjects.
Yao L; Qiu LX; Yu L; Yang Z; Yu XJ; Zhong Y; Hu XC; Yu L
Breast Cancer Res Treat; 2010 Aug; 123(1):227-31. PubMed ID: 20127278
[TBL] [Abstract][Full Text] [Related]
2. The association between XPD Asp312Asn polymorphism and lung cancer risk: a meta-analysis including 16,949 subjects.
Zhang J; Qiu LX; Leaw SJ; Hu XC; Chang JH
Med Oncol; 2011 Sep; 28(3):655-60. PubMed ID: 20354818
[TBL] [Abstract][Full Text] [Related]
3. Xeroderma pigmentosum group D polymorphisms and esophageal cancer susceptibility: a meta-analysis based on case-control studies.
Yang R; Zhang C; Malik A; Shen ZD; Hu J; Wu YH
World J Gastroenterol; 2014 Nov; 20(44):16765-73. PubMed ID: 25469049
[TBL] [Abstract][Full Text] [Related]
4. Associations between XPD Asp312Asn polymorphism and risk of head and neck cancer: a meta-analysis based on 7,122 subjects.
Hu YY; Yuan H; Jiang GB; Chen N; Wen L; Leng WD; Zeng XT; Niu YM
PLoS One; 2012; 7(4):e35220. PubMed ID: 22536360
[TBL] [Abstract][Full Text] [Related]
5. Association between XPD Asp312Asn polymorphism and esophageal cancer susceptibility: a meta-analysis.
Duan XL; Gong H; Zeng XT; Ni XB; Yan Y; Chen W; Liu GL
Asian Pac J Cancer Prev; 2012; 13(7):3299-303. PubMed ID: 22994751
[TBL] [Abstract][Full Text] [Related]
6. XPD Asp312Asn and Lys751Gln polymorphisms and breast cancer susceptibility: a meta-analysis.
Yan Y; Liang H; Light M; Li T; Deng Y; Li M; Li S; Qin X
Tumour Biol; 2014 Mar; 35(3):1907-15. PubMed ID: 24101192
[TBL] [Abstract][Full Text] [Related]
7. Lack of association between XPD Lys751Gln and Asp312Asn polymorphisms and colorectal cancer risk: a meta-analysis of case-control studies.
Zhang Y; Ding D; Wang X; Zhu Z; Huang M; He X
Int J Colorectal Dis; 2011 Oct; 26(10):1257-64. PubMed ID: 21541661
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms of xeroderma pigmentosum group D gene Asp312Asn and Lys751Gln and susceptibility to prostate cancer: a systematic review and meta-analysis.
Ma Q; Qi C; Tie C; Guo Z
Gene; 2013 Nov; 530(2):309-14. PubMed ID: 23973729
[TBL] [Abstract][Full Text] [Related]
9. Xeroderma pigmentosum complementation group D (XPD) gene polymorphisms contribute to bladder cancer risk: a meta-analysis.
Li SX; Dai QS; Chen SX; Zhang SD; Liao XY; Deng X; Chi HB; Li FJ; Zhu JH; Jiang YY
Tumour Biol; 2014 Apr; 35(4):3905-15. PubMed ID: 24347488
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive assessment of associations between ERCC2 Lys751Gln/Asp312Asn polymorphisms and risk of non- Hodgkin lymphoma.
Zhou JY; He LW; Liu J; Yu HL; Wei M; Ma WL; Shi R
Asian Pac J Cancer Prev; 2014; 15(21):9347-53. PubMed ID: 25422223
[TBL] [Abstract][Full Text] [Related]
11. ERCC2 Lys751Gln and Asp312Asn polymorphisms and gastric cancer risk: a meta-analysis.
Chen B; Zhou Y; Yang P; Wu XT
J Cancer Res Clin Oncol; 2011 Jun; 137(6):939-46. PubMed ID: 20981556
[TBL] [Abstract][Full Text] [Related]
12. XPD Lys751Gln and Asp312Asn polymorphisms and gastric cancer susceptibility: a meta-analysis of case-control studies.
Yin QH; Liu C; Hu JB; Meng RR; Li L; Wang YJ
Asian Pac J Cancer Prev; 2013; 14(1):231-6. PubMed ID: 23534729
[TBL] [Abstract][Full Text] [Related]
13. A pooled analysis of the ERCC2 Asp312Asn polymorphism and esophageal cancer susceptibility.
Wen F; Zhao Z; Liu C; Yin Q; Weng J; Wang Y; Ma Y
Tumour Biol; 2014 Apr; 35(4):2959-65. PubMed ID: 24234258
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of two ERCC2 (XPD) polymorphisms, Asp312Asn and Lys751Gln, in breast cancer.
Pabalan N; Francisco-Pabalan O; Sung L; Jarjanazi H; Ozcelik H
Breast Cancer Res Treat; 2010 Nov; 124(2):531-41. PubMed ID: 20379847
[TBL] [Abstract][Full Text] [Related]
15. Impact of two common xeroderma pigmentosum group D (XPD) gene polymorphisms on risk of prostate cancer.
Mi Y; Zhang L; Feng N; Wu S; You X; Shao H; Dai F; Peng T; Qin F; Zou J; Zhu L
PLoS One; 2012; 7(9):e44756. PubMed ID: 23028604
[TBL] [Abstract][Full Text] [Related]
16. XPD polymorphisms, cigarette smoking, and bladder cancer risk: a meta-analysis.
Wang M; Gu D; Zhang Z; Zhou J; Zhang Z
J Toxicol Environ Health A; 2009; 72(11-12):698-705. PubMed ID: 19492231
[TBL] [Abstract][Full Text] [Related]
17. Association between the ERCC2 Asp312Asn polymorphism and risk of cancer.
Xiao F; Pu J; Wen Q; Huang Q; Zhang Q; Huang B; Huang S; Lan A; Zhang Y; Li J; Zhao D; Shen J; Wu H; He Y; Li H; Yang X
Oncotarget; 2017 Jul; 8(29):48488-48506. PubMed ID: 28489582
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in XPD and hOGG1 and prostate cancer risk: a meta-analysis.
Zhu S; Zhang H; Tang Y; Wang J
Urol Int; 2012; 89(2):233-40. PubMed ID: 22890093
[TBL] [Abstract][Full Text] [Related]
19. Association between ERCC2 Lys751Gln polymorphism and the risk of pancreatic cancer, especially among Asians: evidence from a meta-analysis.
Wu Y; Lu ZP; Zhang JJ; Liu DF; Shi GD; Zhang C; Qin ZQ; Zhang JZ; He Y; Wu PF; Miao Y; Jiang KR
Oncotarget; 2017 Jul; 8(30):50124-50132. PubMed ID: 28223548
[TBL] [Abstract][Full Text] [Related]
20. Complex association between ERCC2 gene polymorphisms, gender, smoking and the susceptibility to bladder cancer: a meta-analysis.
Wu Y; Yang Y
Tumour Biol; 2014 Jun; 35(6):5245-57. PubMed ID: 24504678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
